CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2017--
Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos,
Synlogic’s president and chief executive officer, will present at
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at
4:00 p.m. ET on Wednesday, September 27, 2017, in New York City.
A live webcast of the presentation can be accessed under “Event
Calendar” in the Investors & Media section of the Company’s website.
An archived webcast recording will be available on the Synlogic website
for approximately 30 days after the event.
Synlogic is pioneering the development of a novel class of living
treatments, Synthetic BioticTM medicines, based on its
proprietary drug development platform. Synlogic’s initial pipeline
includes Synthetic Biotic medicines for the treatment of rare genetic
diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
In addition, the company is leveraging the broad potential of its
platform to create Synthetic Biotic medicines for the treatment of more
common diseases, including liver disease, inflammatory and immune
disorders, and cancer. Synlogic is collaborating with AbbVie to develop
Synthetic Biotic-based treatments for inflammatory bowel disease (IBD).
For more information, please visit www.synlogictx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920006089/en/
Elizabeth Wolffe, Ph.D.,